Cardiovascular implications of thiazolidinedione therapy

Progress in Cardiovascular Nursing
Robert E Lamb, Deborah King

Abstract

The incidence of obesity and type 2 diabetes mellitus (DM2) in the United States has been increasing dramatically over the past 15 years, and is now at epidemic proportions. DM2 is the clinical manifestation of a long-term metabolic process that is initiated by cells' decreased sensitivity to the actions of insulin. Many outcome studies have identified DM2 as a strong and independent risk factor for the development of cardiovascular complications such as hypertension, arteriosclerosis, and heart failure. The goals of therapy in treating DM2 are to improve the long-term outlook for these patients. However, in selecting a therapeutic regimen for patients, clinicians should be aware that potentially severe adverse events may occur at a rate not previously identified in phase 3 studies. Certain therapies used to treat DM2, by effectively increasing the sensitivity of insulin, have also been reported to cause adverse effects, which can precipitate symptomatic heart failure. The purpose of this column is to discuss the therapeutic options available for treating patients with DM2, the potential pathophysiology of the adverse events of symptomatic heart failure, encouragement of use of the US Food and Drug Administration MedWatch progr...Continue Reading

References

Aug 1, 1994·British Heart Journal·A J CoatsP A Poole-Wilson
May 22, 1996·JAMA : the Journal of the American Medical Association·D LevyK K Ho
Aug 1, 1997·Journal of the American College of Cardiology·J W SwanA J Coats
Dec 2, 1998·Basic Research in Cardiology·G Nickenig, M Böhm
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Feb 24, 2001·Annals of Internal Medicine·A A ParulkarV A Fonseca
Feb 28, 2001·Diabetes, Obesity & Metabolism·B Balkau, E Eschwège
Feb 28, 2001·Diabetes, Obesity & Metabolism·E Standl
Feb 28, 2001·Diabetes, Obesity & Metabolism·W DoehnerA J Coats
Sep 18, 2001·JAMA : the Journal of the American Medical Association·A H MokdadJ P Koplan
Jul 2, 2002·Journal of Lipid Research·Kaspar BerneisRonald M Krauss
Apr 23, 2003·Journal of the American College of Cardiology·W H Wilson TangJames B Young
Jun 11, 2003·Journal of Clinical Pharmacy and Therapeutics·P PeterM J Kendall
Jul 3, 2003·JAMA : the Journal of the American Medical Association·Frederick A MasoudiHarlan M Krumholz
Sep 10, 2003·Mayo Clinic Proceedings·Asra Kermani, Abhimanyu Garg
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Oct 9, 2003·JAMA : the Journal of the American Medical Association·K M Venkat NarayanDavid F Williamson
Dec 18, 2003·The American Journal of Medicine·Norman K Hollenberg
Apr 2, 2004·International Journal of Clinical Practice·I W Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.